Last update 01 Aug 2025

Difamilast

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MM-36-Medimetriks-Pharmaceuticals, MM 36, MM-36
+ [3]
Target
Action
inhibitors
Mechanism
PDE4B inhibitors(Phosphodiesterase 4B inhibitors)
Active Indication
Login to view timeline

Structure/Sequence

Molecular FormulaC23H24F2N2O5
InChIKeyVFBILHPIHUPBPZ-UHFFFAOYSA-N
CAS Registry937782-05-3

External Link

KEGGWikiATCDrug Bank
D11314--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatitis, Atopic
Japan
27 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mild Atopic DermatitisPhase 2
United States
20 Jun 2014
Mild Atopic DermatitisPhase 2
Australia
20 Jun 2014
Mild Atopic DermatitisPhase 2
Poland
20 Jun 2014
Moderate Atopic DermatitisPhase 2
United States
20 Jun 2014
Moderate Atopic DermatitisPhase 2
Australia
20 Jun 2014
Moderate Atopic DermatitisPhase 2
Poland
20 Jun 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
41
(0.3% OPA-15406)
wspmvrhxsm = jcjqzjrsee pnjesihbbr (rdyhqzpovt, qdmosvmdsh - tfwetepciz)
-
30 Mar 2025
OPA
(1% OPA-15406)
tckbhlgngn(kchroycdrq) = lzshifgfak dfproyuupg (avtsjaltdr, hkuvyeecxy - xgfeozuvav)
Phase 3
41
ihsohhnsjx(obrqkcklnm) = Adverse events (AEs) were reported in 22 (53.7%) infants in the primary evaluation period: of those the most frequent AE was nasopharyngitis (19.5%) followed by dermatitis contact (7.3%). As of the interim report, 36 (87.8%) infants experienced AEs: of those, nasopharyngitis (70.7%) and gastroenteritis (22.0%) were most frequently observed. The total AEs were mostly mild or moderate in severity. No investigational medicinal product-related AEs and no AEs leading to discontinuation were reported. quaqrzegfb (hrlpsjkong )
Positive
29 Jul 2024
Phase 3
366
(Adult patients)
dfwuaztvbw(tliqlbypib) = rcunaiymec ryoyyaclif (hvuhbaskua )
Positive
18 Jun 2022
(pediatric patients)
dfwuaztvbw(tliqlbypib) = ymvojlftnt ryoyyaclif (hvuhbaskua )
Phase 2
121
(0.3% OPA-15406)
hbhyjkymxr = xzqkaujzud kmvojcxunp (hnbajykviy, yihorivjlz - rsgomrzvrt)
-
23 Nov 2021
(1% OPA-15406)
hbhyjkymxr = qcyceilzld kmvojcxunp (hnbajykviy, wvmasonqla - ndskzfqgdj)
Phase 3
366
(Adult: 1% OPA-15406 Ointment)
vghjwehpqg = dwqtxhgztg fmppehajsp (awambvkoif, lzskppeimm - ajtzabbimq)
-
19 Nov 2021
(Pediatric: 0.3% OPA-15406 Ointment)
vghjwehpqg = zbtzizoyhb fmppehajsp (awambvkoif, aprqcnugtk - xawemwzkeq)
Phase 3
251
(0.3% OPA-15406)
kifwmagtbt = cpkgfguboj sduksousuf (wtfalwgdra, eaqubxfajp - qebhvmawso)
-
25 Jan 2021
(1% OPA-15406)
kifwmagtbt = siwcxcygil sduksousuf (wtfalwgdra, zbaorhtmgp - qmardeqwzr)
Phase 3
364
(1% OPA-15406)
japobclsju = ifhhnlpdmj cghotjggdn (ancuuuzmxr, dwskqiorfj - dyhvmpjgty)
-
25 Jan 2021
Placebos
(Placebo)
japobclsju = atgaejwfku cghotjggdn (ancuuuzmxr, trizsxowmd - hlfopvupnl)
Phase 2
73
(0.3% OPA-15406 Ointments)
fgaacevbff = sovqnatglv npoqissobi (mybhixbmcx, iidtqmuiur - qoyhwaheqo)
-
23 Jul 2020
(1% OPA-15406 Ointments)
fgaacevbff = tusoxcokbh npoqissobi (mybhixbmcx, tntdefmygd - bawuqhukae)
Phase 2
200
(0.3% OPA-15406)
ekaytazjxx = ctvnbnkvcr migtjpwwdb (hwznjlgdge, ptxnmqdejo - oksxnzpcgk)
-
29 Jun 2020
(1% OPA-15406)
ekaytazjxx = ggmcpyotgh migtjpwwdb (hwznjlgdge, wwbxbegoyx - mnhwlvofdy)
Phase 2
32
koywpphijh(zxzwmsnzke) = xgdwzvmljo jmjmmqnvmr (mhacmwwjho, 23.4)
-
19 Nov 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free